| Literature DB >> 20459855 |
Wang-hong Xu1, Xiao-nan Ruan, Xiao-jin Fu, Qiu-li Zhu, Hong Zhang, Yun Bai, Hong-yan Wu, Yi Zhou, Hua Qiu, Qiao Sun, Qing-wu Jiang, Li-ming Yang, Jian-jun Gu, Gen-ming Zhao.
Abstract
BACKGROUND: The prevalence of metabolic syndrome (MS) has been increasing in China in recent years. The aim of this study is to estimate and compare the prevalence of MS among Chinese adults in Shanghai, one of the most economic developed areas in China, using definitions proposed by World Health Organization (WHO), National Cholesterol Education Program Adult Treatment Panel (modified ATP III) and International Diabetes Federation (IDF).Entities:
Mesh:
Year: 2010 PMID: 20459855 PMCID: PMC2889866 DOI: 10.1186/1471-2458-10-246
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Measured metabolic characteristics of the selected Chinese adults in Pudong New Area of Shanghai, China
| Characteristics | Male (N = 2477) | Female (N = 3107) | P value |
|---|---|---|---|
| Mean ± SD | 83.9 ± 9.2 | 78.3 ± 9.4 | <0.0001 |
| ≥ 90 cm for male | 22.1 | ||
| ≥ 80 cm for female | 38.5 | <0.0001 | |
| Mean ± SD | 24.1 ± 3.3 | 23.8 ± 3.5 | <0.0001 |
| ≥ 30 kg/m2 | 4.5 | 5.3 | 0.16 |
| Mean ± SD | 0.88 ± 0.06 | 0.83 ± 0.07 | <0.0001 |
| >0.90 for male | 38.3 | ||
| >0.85 for female | 37.9 | 0.93 | |
| Mean ± SD | 128 ± 16.1 | 126 ± 19.6 | <0.0001 |
| ≥ 130 mmHg | 40.3 | 37.5 | 0.03 |
| Mean ± SD | 81 ± 9.5 | 80 ± 10.1 | <0.0001 |
| ≥ 85 mmHg | 27.0 | 24.6 | 0.05 |
| Mean ± SD | 5.8 ± 1.9 | 5.7 ± 1.6 | 0.0003 |
| >5.6 mmol/l | 35.9 | 31.4 | 0.0006 |
| Mean ± SD | 1.34 ± 0.26 | 1.48 ± 0.27 | <0.0001 |
| <1.036 mmol/l for male | 11.1 | ||
| <1.295 mmol/l for female | 25.8 | <0.0001 | |
| Mean ± SD | 2.4 ± 2.1 | 2.1 ± 1.7 | 0.0001 |
| >1.695 mmol/l | 56.5 | 47.0 | <0.0001 |
| Mean ± SD | 2.0 ± 9.2 | 2.8 ± 11.1 | <0.0001 |
| ≥ 30 mg/g | 0.8 | 1.6 | 0.0035 |
P value for t-test (continuous variables) or χ2 test (categorical variables).
Sex and age-specific prevalence of the MS according to WHO, modified ATP III and IDF definition among selected Chinese adults in Pudong New Area of Shanghai, China
| No. of Subjects | WHO criteria | ATP III criteria | IDF criteria | ||||
|---|---|---|---|---|---|---|---|
| No. of MS | % | No. of MS | % | No. of MS | % | ||
| 2477 | 498 | 20.2(15.3) | 696 | 28.4(22.7) | 391 | 15.9(13.8) | |
| 20- | 141 | 3 | 2.1 | 10 | 7.1 | 9 | 6.4 |
| 25- | 124 | 6 | 4.9 | 17 | 14.1 | 14 | 11.6 |
| 30- | 134 | 8 | 6.1 | 16 | 12.2 | 12 | 9.2 |
| 35- | 142 | 22 | 15.8 | 26 | 18.7 | 17 | 12.2 |
| 40- | 204 | 35 | 17.2 | 54 | 26.7 | 34 | 16.8 |
| 45- | 314 | 55 | 17.5 | 74 | 23.7 | 38 | 12.2 |
| 50- | 309 | 76 | 19.6 | 114 | 29.5 | 61 | 15.8 |
| 55- | 348 | 85 | 24.6 | 117 | 33.9 | 61 | 17.7 |
| 60- | 258 | 80 | 31.3 | 103 | 40.2 | 51 | 19.9 |
| 65- | 162 | 51 | 31.7 | 68 | 42.5 | 38 | 23.8 |
| 70- | 173 | 44 | 25.4 | 62 | 35.8 | 34 | 19.7 |
| 75- | 88 | 33 | 37.5 | 35 | 40.2 | 22 | 25.3 |
| 3107 | 575 | 18.7(12.3) | 1078 | 35.1(25.0) | 821 | 26.7(19.2) | |
| 20- | 159 | 0 | 0 | 3 | 1.9 | 3 | 1.9 |
| 25- | 176 | 3 | 1.8 | 15 | 8.8 | 14 | 8.2 |
| 30- | 156 | 3 | 1.9 | 13 | 8.4 | 10 | 6.5 |
| 35- | 186 | 8 | 4.4 | 33 | 17.9 | 28 | 15.2 |
| 40- | 274 | 20 | 7.4 | 48 | 17.8 | 34 | 12.6 |
| 45- | 395 | 59 | 15.0 | 113 | 28.8 | 83 | 21.1 |
| 50- | 551 | 98 | 17.9 | 205 | 37.6 | 149 | 27.3 |
| 55- | 468 | 123 | 26.5 | 210 | 45.2 | 172 | 37.0 |
| 60- | 265 | 80 | 30.2 | 147 | 55.5 | 110 | 41.5 |
| 65- | 189 | 59 | 31.9 | 96 | 52.5 | 71 | 38.8 |
| 70- | 188 | 75 | 39.9 | 130 | 69.5 | 99 | 52.9 |
| 75- | 100 | 47 | 47.5 | 65 | 65.7 | 48 | 48.5 |
In parentheses was the age-standardized prevalence of the MS according to age distribution of the world population.
Prevalence of individual metabolic abnormalities among selected Chinese adults in Pudong New Area of Shanghai, China
| Metabolic abnormalities | Male (2477) | Female (3107) | Total (5583) | |||
|---|---|---|---|---|---|---|
| Number | % | Number | % | Number | % | |
| Impaired FPG or diabetes | 903 | 36.7 | 992 | 32.2 | 1895 | 34.2 |
| Central obesity | 973 | 39.3 | 1224 | 39.4 | 2197 | 39.3 |
| Elevated BP or hypertension | 778 | 31.4 | 927 | 29.8 | 1705 | 30.5 |
| Microalbuminuria | 19 | 0.8 | 51 | 1.6 | 70 | 1.3 |
| Hyperlipidemia | 1409 | 56.9 | 1485 | 47.8 | 2894 | 51.8 |
| No. of metabolic abnormalities | ||||||
| 0 | 483 | 19.6 | 859 | 27.9 | 1342 | 24.2 |
| 1 | 682 | 27.7 | 791 | 25.7 | 1473 | 26.6 |
| 2 | 675 | 27.4 | 696 | 22.6 | 1371 | 24.8 |
| 3 | 455 | 18.5 | 495 | 16.1 | 950 | 18.2 |
| 4 | 161 | 6.5 | 226 | 7.3 | 387 | 7.0 |
| 5 | 4 | 0.2 | 13 | 0.4 | 17 | 0.3 |
| Increased WC | 548 | 22.1 | 1196 | 38.5 | 1744 | 31.2 |
| Elevated BP or hypertension | 1213 | 49.0 | 1393 | 44.8 | 2606 | 46.7 |
| Reduced HDL-C or use drug | 272 | 11.1 | 795 | 25.8 | 1067 | 19.3 |
| Elevated TG or use drug | 1455 | 59.2 | 1532 | 49.7 | 2987 | 54.0 |
| Impaired FPG or diabetes | 903 | 36.7 | 992 | 32.2 | 1895 | 34.2 |
| No. of metabolic abnormalities | ||||||
| 0 | 418 | 17.0 | 667 | 21.7 | 1085 | 19.6 |
| 1 | 663 | 27.0 | 677 | 22.0 | 1340 | 24.2 |
| 2 | 676 | 27.6 | 652 | 21.2 | 1328 | 24.0 |
| 3 | 460 | 18.8 | 557 | 18.1 | 1017 | 18.4 |
| 4 | 206 | 8.4 | 385 | 12.5 | 591 | 10.7 |
| 5 | 30 | 1.2 | 136 | 4.4 | 168 | 3.0 |
Figure 1Prevalence of the MS according to WHO, modified ATP III and IDF criteria in all participants and the subjects with each individual metabolic abnormality.
Association of individual metabolic abnormalities with the MS among selected Chinese adults in Pudong New Area of Shanghai, China
| Metabolic abnormalities | MS by WHO | MS by ATP III | MS by IDF | |||
|---|---|---|---|---|---|---|
| No/Yes | OR(95%CI) | No/Yes | OR(95%CI) | No/Yes | OR(95%CI) | |
| Impaired FPG or diabetes | ||||||
| No | 1557/0 | -- | 1379/176 | 1.0 | 1413/142 | 1.0 |
| Yes | 405/498 | -- | 377/521 | 9.6(7.8-11.9) | 648/250 | 3.5(2.8-4.4) |
| Central obesity (WC > 90 cm) | ||||||
| No | 1632/279 | 1.0 | 1602/305 | 1.0 | 1907/0 | -- |
| Yes | 329/219 | 3.9(3.1-4.8) | 154/392 | 14.9(11.8-18.9) | 154/392 | -- |
| Hypertension or elevated BP (sbp ≥ 130 or dbp ≥ 85 mmHg) | ||||||
| No | 1143/107 | 1.0 | 1151/96 | 1.0 | 1170/77 | 1.0 |
| Yes | 819/391 | 4.1(3.2-5.2) | 605/601 | 10.7(8.4-13.7) | 891/315 | 5.1(3.9-6.7) |
| Microalbuminuria | ||||||
| No | 1956/485 | 1.0 | 1748/687 | 1.0 | 2049/386 | 1.0 |
| Yes | 6/13 | 6.8(2.5-18.7) | 8/10 | 2.4(0.9-6.1) | 12/6 | 2.1(0.8-5.8) |
| Reduced HDL-C or use druga | ||||||
| No | 1770/416 | 1.0 | 1681/502 | 1.0 | 1893/290 | 1.0 |
| Yes | 192/80 | 1.5(1.1-2.0) | 75/195 | 9.9(7.2-13.8) | 168/102 | 3.2(2.3-4.6) |
| Elevated TG or use druga | ||||||
| No | 950/50 | 1.0 | 950/49 | 1.0 | 953/46 | 1.0 |
| Yes | 1009/446 | 7.6(5.5-10.4) | 806/648 | 15.9(11.3-22.2) | 1108/346 | 5.1(3.5-7.4) |
| Dyslipidemia (reduced HDL-C or elevated TG)a | ||||||
| No | 1007/60 | 1.0 | 986/76 | 1.0 | 1001/61 | 1.0 |
| Yes | 955/438 | 7.4(5.5-10.0) | 770/621 | 10.9(8.2-14.6) | 1060/331 | 4.2(3.0-5.8) |
| Impaired FPG or diabetes | ||||||
| No | 2088/0 | -- | 1706/380 | 1.0 | 1757/329 | 1.0 |
| Yes | 417/575 | -- | 288/700 | 8.4(7.0-10.1) | 495/493 | 3.9(3.3-4.7) |
| Central obesity (WC > 85 cm) | ||||||
| No | 1427/166 | 1.0 | 1631/258 | 1.0 | 1889/0 | -- |
| Yes | 778/409 | 4.0(3.3-4.9) | 363/822 | 12.0(10.0-14.5) | 363/822 | -- |
| Hypertension or elevated BP (sbp ≥ 130 or dbp ≥ 85 mmHg) | ||||||
| No | 1590/103 | 1.0 | 1484/205 | 1.0 | 1515/174 | 1.0 |
| Yes | 915/472 | 4.9(3.8-6.2) | 510/875 | 8.3(6.8-10.0) | 737/648 | 5.3(4.3-6.5) |
| Microalbuminuria | ||||||
| No | 2489/540 | 1.0 | 1983/1040 | 1.0 | 2235/788 | 1.0 |
| Yes | 16/35 | 7.8(4.0-15.3) | 11/40 | 5.3(2.5-11.2) | 17/34 | 4.1(2.2-7.8) |
| Reduced HDL-C or use druga | ||||||
| No | 1951/333 | 1.0 | 1738/543 | 1.0 | 1841/440 | 1.0 |
| Yes | 553/241 | 2.3(1.8-2.8) | 256/537 | 10.4(8.2-13.1) | 411/382 | 4.0(3.2-5.0) |
| Elevated TG or use druga | ||||||
| No | 1485/62 | 1.0 | 1432/115 | 1.0 | 1440/107 | 1.0 |
| Yes | 1017/511 | 7.3(5.4-9.7) | 562/965 | 16.5(12.9-21.2) | 812/715 | 7.7(6.0-9.9) |
| Dyslipidemia (reduced HDL-C or elevated TG)a | ||||||
| No | 1547/73 | 1.0 | 1456/161 | 1.0 | 1475/142 | 1.0 |
| Yes | 958/502 | 7.1(5.4-9.4) | 538/919 | 12.1(9.7-15.2) | 777/680 | 5.9(4.7-7.5) |
OR: Adjusted for age as a continuous variable.
a additionally adjusted for BMI (as a continuous variable), cigarette smoking (Never/Ever), alcohol consumption (Never/Ever) and exercise (Never/ever).
Figure 2Overall prevalence of the MS among selected Chinese adults in Pudong New Area of Shanghai, China, according to WHO, modified ATP III and IDF criteria.
Agreement of WHO, modified ATP III and IDF criteria in identifying the MS among selected Chinese adults in Pudong New Area of Shanghai, China
| WHO criteria | κ | 95%CI | ATP III criteria | κ | 95%CI | |||
|---|---|---|---|---|---|---|---|---|
| + | - | + | - | |||||
| ATP III criteria | ||||||||
| + | 434 | 276 | -- | -- | ||||
| - | 73 | 1670 | 0.617 | 0.611-0.622 | -- | -- | -- | |
| IDF criteria | ||||||||
| + | 220 | 177 | 397 | 0 | ||||
| - | 287 | 1769 | 0.382 | 0.377-0.387 | 313 | 1743 | 0.647 | 0.643-0.652 |
| ATP III criteria | ||||||||
| + | 553 | 532 | -- | -- | ||||
| - | 27 | 1962 | 0.552 | 0.547-0.558 | -- | -- | -- | |
| IDF criteria | ||||||||
| + | 413 | 414 | 827 | 0 | ||||
| - | 167 | 2080 | 0.469 | 0.464-0.474 | 258 | 1989 | 0.806 | 0.802-0.810 |
P < 0.01 for all κ statistics.